Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20952821 | 0.84 | MEN1 (0.52) | MEN1FAAHMAPK1KMT2AHPGD | |
| SCHEMBL26869086 | 0.83 | CNR2 (0.34) | CNR2ALOX5 | |
| SCHEMBL30103426 | 0.81 | FAAH (0.58) | MEN1FAAHMAPK1KMT2AHPGD | |
| SCHEMBL2120346 | 0.77 | FAAH (0.61) | MEN1FAAHMAPK1KMT2AHPGD | |
| SCHEMBL22355749 | 0.76 | FAAH (0.44) | MEN1FAAHMAPK1KMT2AHPGD | |
| SCHEMBL19369832 | 0.76 | ALOX5 (0.34) | ALDH1A1ALOX5 | |
| SCHEMBL21472808 | 0.76 | MEN1 (0.46) | MEN1FAAHMAPK1KMT2AHPGD | |
| SCHEMBL19369584 | 0.76 | ALOX5 (0.34) | ALDH1A1ALOX5 | |
| SCHEMBL19369827 | 0.76 | ALOX5 (0.34) | ALDH1A1ALOX5 | |
| SCHEMBL19369833 | 0.76 | ALOX5 (0.34) | ALDH1A1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | MEN1 4753/4885FAAH 2901/4885MAPK1 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.